Suppression of premature termination codons as a therapeutic approach

Academic Article

Abstract

  • In this review, we describe our current understanding of translation termination and pharmacological agents that influence the accuracy of this process. A number of drugs have been identified that induce suppression of translation termination at in-frame premature termination codons (PTCs; also known as nonsense mutations) in mammalian cells. We discuss efforts to utilize these drugs to suppress disease-causing PTCs that result in the loss of protein expression and function. In-frame PTCs represent a genotypic subset of mutations that make up ∼11% of all known mutations that cause genetic diseases, and millions of patients have diseases attributable to PTCs. Current approaches aimed at reducing the efficiency of translation termination at PTCs (referred to as PTC suppression therapy) have the goal of alleviating the phenotypic consequences of a wide range of genetic diseases. Suppression therapy is currently in clinical trials for treatment of several genetic diseases caused by PTCs, and preliminary results suggest that some patients have shown clinical improvements. While current progress is promising, we discuss various approaches that may further enhance the efficiency of this novel therapeutic approach. © 2012 Informa Healthcare USA, Inc.
  • Digital Object Identifier (doi)

    Pubmed Id

  • 7085752
  • Author List

  • Keeling KM; Wang D; Conard SE; Bedwell DM
  • Start Page

  • 444
  • End Page

  • 463
  • Volume

  • 47
  • Issue

  • 5